Skip to content

Study · Case report or series · n = 1 · 2026

5 results

Melanocortin-4 Receptor Agonist Treatment of Hypothalamic Obesity in ROHHAD Syndrome.

Grünewald A, Steidel E, Müntjes C, Hühne T, Degenhardt F, Stehling F, Cetiner M

Pediatrics1 Jun 2026

PMID42114845 (opens in a new tab)DOI10.1542/peds.2025-074432 (opens in a new tab)PepBankPUB-42114845
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a boy with ROHHAD syndrome, setmelanotide treatment was followed by 28% weight loss, from 97 to 70 kg.

    In plain wordsA boy with ROHHAD syndrome lost 28% of his weight, from 97 to 70 kg, with setmelanotide.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    28%
    setmelanotide
    Body weight before
    97 kg
    setmelanotide
    Body weight after
    70 kg
    setmelanotide

    Source sentences

    Summary
    Setmelanotide induced meaningful improvements, including substantial weight loss (28%, from 97 to 70 kg)
    2 context sentences
    Summary · context
    In light of the patient's progressive weight gain, intractable appetite, ventilator dependence, metabolic dysfunction-associated steatotic liver disease and behavioral dysregulation, including aggressive outbursts posing significant risk to self and others, we initiated off-label treatment with setm…
    Summary · context
    For the past 2 years, we have been treating a boy, now aged 12 years, with ROHHAD syndrome.
  2. 02HumanCase report or seriesEfficacy outcome

    In a boy with ROHHAD syndrome, setmelanotide treatment was followed by hepatic steatosis regression on attenuation imaging.

    In plain wordsIn a boy with ROHHAD syndrome, liver fat decreased during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHepatic steatosis
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide induced meaningful improvements, including substantial weight loss (28%, from 97 to 70 kg), measurable regression of hepatic steatosis as quantified by ultrasonography-based attenuation imaging, reduced ventilatory support, and a marked improvement in behavioral disorders that permitte…
    1 context sentence
    Summary · context
    For the past 2 years, we have been treating a boy, now aged 12 years, with ROHHAD syndrome.
  3. 03HumanCase report or seriesEfficacy outcome

    In a boy with ROHHAD syndrome, ventilatory support decreased with setmelanotide treatment.

    In plain wordsA boy with ROHHAD syndrome needed less breathing support during setmelanotide treatment.

    Peptide
    Setmelanotide
    Outcome
    DecreaseVentilatory support
    Study

    n = 1

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide induced meaningful improvements, including substantial weight loss (28%, from 97 to 70 kg), measurable regression of hepatic steatosis as quantified by ultrasonography-based attenuation imaging, reduced ventilatory support, and a marked improvement in behavioral disorders that permitte…
    1 context sentence
    Summary · context
    For the past 2 years, we have been treating a boy, now aged 12 years, with ROHHAD syndrome.
  4. 04HumanCase report or seriesEfficacy outcome

    In a boy with ROHHAD syndrome, behavioral disorders improved with setmelanotide, permitting antipsychotic medication tapering.

    In plain wordsIn a boy with ROHHAD syndrome, behavior improved during setmelanotide treatment, permitting less antipsychotic medication.

    Peptide
    Setmelanotide
    Outcome
    Not applicableBehavioral disorders
    Study

    n = 1

    Outcome group
    Locomotor and behavioral activity · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide induced meaningful improvements, including substantial weight loss (28%, from 97 to 70 kg), measurable regression of hepatic steatosis as quantified by ultrasonography-based attenuation imaging, reduced ventilatory support, and a marked improvement in behavioral disorders that permitte…
    1 context sentence
    Summary · context
    For the past 2 years, we have been treating a boy, now aged 12 years, with ROHHAD syndrome.
  5. 05HumanCase report or seriesEfficacy outcome

    After setmelanotide discontinuation following 18 months of therapy, a boy with ROHHAD gained 10% weight within 3 months, from 70 to 77 kg.

    In plain wordsAfter setmelanotide stopped, a boy with ROHHAD gained 10% weight within 3 months, from 70 to 77 kg.

    Peptide
    Setmelanotide
    Outcome
    IncreaseWeight gain after discontinuation
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 18 months of therapy before discontinuationAs given in this study (human).

    Measurements

    Weight gain after discontinuation
    10%
    within 3 months after stopping setmelanotide
    Body weight before
    70 kg
    at discontinuation
    Body weight after
    77 kg
    within 3 months after stopping

    Source sentences

    Summary
    After 18 months of therapy, insurance coverage for the off-label use was refused, and treatment was discontinued, which resulted in significant weight gain within 3 months (10%, from 70 to 77 kg).
    1 context sentence
    Summary · context
    For the past 2 years, we have been treating a boy, now aged 12 years, with ROHHAD syndrome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.